8-K: Jackson Acquisition Co II Faces NYSE Delisting Threat

Jackson Acquisition Company II received a notice from the NYSE for failing to meet the minimum 300 public stockholders requirement, initiating a compliance period.

Summary

• Jackson Acquisition Company II (JACS) received a notice from the New York Stock Exchange (NYSE) on February 6, 2026, indicating non-compliance with Section 802.01B of the NYSE Listed Company Manual.
• The non-compliance stems from the company's failure to maintain a minimum of 300 public stockholders on a continuous basis.
• JACS must submit a business plan to the NYSE within 45 days of receiving the notice, demonstrating how it expects to regain compliance within 18 months.
• The NYSE will review the plan within 45 days, and if approved, JACS's securities will continue to be listed and traded during the 18-month cure period, subject to other listing standards and periodic review.
• Failure to comply with the plan or NYSE's non-acceptance of the plan could lead to suspension and delisting procedures.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development due to the direct threat of delisting, which introduces substantial uncertainty and risk for shareholders, despite the company's stated plan to regain compliance.

Positives

• The notice has no immediate impact on the listing or trading of the company's securities.
• The company has an 18-month period to regain compliance if its business plan is approved by the NYSE.
• Management plans to promptly submit a business plan to address the non-compliance.

Negatives

• The company is not in compliance with NYSE Listing Rule 802.01B, requiring a minimum of 300 public stockholders.
• Failure to regain compliance within the specified timeframe could result in the suspension and delisting of the company's securities from the NYSE.

Risks

• Potential delisting of the company's securities from the New York Stock Exchange if it fails to submit an acceptable business plan or does not regain compliance with the minimum public stockholder requirement within 18 months.
• Uncertainty regarding the NYSE's approval of the submitted business plan.
• Risk of not meeting other NYSE listing standards during the cure period.

Future Outlook

The company intends to promptly submit a business plan to the NYSE within 45 days to demonstrate how it expects to return to compliance with the minimum public stockholder requirement within 18 months of receiving the notice. If the plan is approved, the company's securities will continue to be listed and traded on the NYSE during this cure period, subject to ongoing compliance with other listing standards.

Management Comments

• The Company plans to promptly submit a business plan that demonstrates how the Company expects to return to compliance with the Listing Rule within 18 months of receipt of the Notice.

Industry Context

StockSavvy.ai notes that SPACs, like Jackson Acquisition Company II, often face unique challenges in maintaining listing compliance, particularly regarding shareholder counts, as their initial public offering structure and subsequent de-SPAC transactions can lead to fluctuations in public ownership. This non-compliance highlights the ongoing scrutiny by exchanges on SPACs to ensure they meet continuous listing standards, which is crucial for investor confidence and market integrity.

Comparison to Industry Standards

• StockSavvy.ai observes that maintaining a minimum of 300 public stockholders is a standard NYSE requirement for listed companies, designed to ensure sufficient liquidity and public interest.
• While specific comparable companies facing this exact issue are not detailed in the filing, similar situations have arisen for other smaller-cap or SPAC entities post-IPO or de-SPAC, where shareholder dispersion can be a challenge. For instance, some smaller biotech or technology SPACs have struggled with maintaining public float and shareholder numbers after their initial business combinations.
• The 18-month cure period is a standard allowance by the NYSE for companies to rectify such deficiencies, providing a structured pathway back to compliance, similar to what was offered to companies like [Hypothetical Company A] in [Year] for similar listing issues.

Stakeholder Impact

• Shareholders: Face increased risk of delisting, which could negatively impact liquidity and share price. Uncertainty regarding the company's future listing status.
• Investors: Potential for reduced investor confidence due to regulatory non-compliance.

Next Steps

• Jackson Acquisition Company II will submit a business plan to the NYSE within 45 days of February 6, 2026.
• The NYSE will review the submitted business plan within 45 days.
• If the plan is approved, the company will work to regain compliance with the minimum public stockholder requirement within 18 months of February 6, 2026.
• The NYSE will periodically review the company's progress under the plan.

Key Dates

Recommendation

The notice of non-compliance with NYSE listing standards, specifically the failure to maintain a minimum of 300 public stockholders, introduces significant uncertainty and a direct risk of delisting. While the company has a plan to address this, the outcome is not guaranteed, and delisting would severely impair liquidity and potentially the value of the shares. A seasoned investor would likely consider selling to avoid this substantial regulatory risk, especially given the nature of a SPAC where the underlying business combination is still pending.

Keywords

Jackson Acquisition Company II, JACS, NYSE, Delisting, Non-compliance, SPAC, Public Stockholders, Listing Rule 802.01B, Healthcare Services, Healthcare Technology